T1c cancer: what is it?
With the advent of more-routine prostate-specific antigen (PSA) blood testing, many more patients are being identified in whom the only clinical sign of their underlying disease is an elevated PSA level. Most evidence to date suggests that such patients do harbor clinically significant cancers and thus should be treated in a fashion similar to patients with T1b, T2a, and T2b disease.
Department of Urology, Loyola University Medical Center, Maywood, IL, USA.
R C
RC
Flanigan
W S
WS
Dougherty
D004273:DNA, Neoplasm / Q000235:genetics; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011003:Ploidies; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D012720:Severity of Illness Index
D004273:DNA, Neoplasm; D017430:Prostate-Specific Antigen